These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 36395065

  • 1. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Krow-Lucal E, Marin M, Shepersky L, Bahta L, Loehr J, Dooling K.
    MMWR Morb Mortal Wkly Rep; 2022 Nov 18; 71(46):1465-1470. PubMed ID: 36395065
    [Abstract] [Full Text] [Related]

  • 2. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Jun 14; 62(RR-04):1-34. PubMed ID: 23760231
    [Abstract] [Full Text] [Related]

  • 3. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 May 07; 59(RR-3):1-12. PubMed ID: 20448530
    [Abstract] [Full Text] [Related]

  • 4. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L.
    MMWR Recomm Rep; 1998 May 22; 47(RR-8):1-57. PubMed ID: 9639369
    [Abstract] [Full Text] [Related]

  • 5. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N, Jansson UB, Alm B.
    Vaccine; 2006 Jul 26; 24(31-32):5800-5. PubMed ID: 16765490
    [Abstract] [Full Text] [Related]

  • 6. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K, Goa KL.
    Drugs; 2003 Jul 26; 63(19):2107-26. PubMed ID: 12962524
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O.
    Hum Vaccin Immunother; 2018 Jul 26; 14(11):2624-2631. PubMed ID: 29902133
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
    Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O.
    J Pediatric Infect Dis Soc; 2020 Apr 30; 9(2):194-201. PubMed ID: 30849175
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
    Usonis V, Bakasenas V, Chitour K, Clemens R.
    Infection; 1998 Apr 30; 26(4):222-6. PubMed ID: 9717679
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination.
    Mahamud A, Masunu-Faleafaga Y, Walls L, Williams N, Garcia P, Teshale E, Williams R, Dulski T, Bellini WJ, Kutty PK.
    Vaccine; 2013 Aug 12; 31(36):3683-7. PubMed ID: 23770334
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F, Heffernan C, Meurice F, Ota MOC, Vetter V, Casabona G.
    Expert Rev Vaccines; 2021 Jul 12; 20(7):811-826. PubMed ID: 34096442
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martínez D, Trumbo SP, Fernández de Castro J.
    Vaccine; 2017 May 25; 35(23):3116-3122. PubMed ID: 28457672
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers.
    Hyle EP, Rao SR, Bangs AC, Gastañaduy P, Fiebelkorn AP, Hagmann SHF, Walker AT, Walensky RP, Ryan ET, LaRocque RC.
    JAMA Pediatr; 2020 Feb 01; 174(2):e194515. PubMed ID: 31816033
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.